CRIS missed EPS expectations by 42.45%
Nov 22, 2024, 11:31 AM
0.00%
What does CRIS do
Curis, headquartered in Lexington, Massachusetts, focuses on developing cancer treatments, including emavusertib for various lymphomas and leukemias, alongside other candidates like Fimepinostat and CA-170. The company, which went public in 2000, employs 48 full-time staff.
Curis (CRIS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Curis's actual EPS was -$1.70, missing the estimate of -$1.19 per share, resulting in a -42.45% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.